Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2003
10/02/2003WO2003080075A1 Ameliorant for chemical treatment of cancer
10/02/2003WO2003080074A1 Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
10/02/2003WO2003080073A1 Hemostatic dressing
10/02/2003WO2003080072A1 Preemptive prophylaxis of migraine
10/02/2003WO2003080071A1 Novel therapeutical use of agonist ligands specific to g2a receptor
10/02/2003WO2003080070A2 Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
10/02/2003WO2003080069A1 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
10/02/2003WO2003080068A1 Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
10/02/2003WO2003080066A1 Use of devazepide for the treatment of constipation
10/02/2003WO2003080064A1 Kinase inhibitors
10/02/2003WO2003080063A1 PREVENTIVES OR REMEDIES FOR DISEAES CAUSED BY eNOS EXPRESSION
10/02/2003WO2003080062A1 Composition comprising vitamin b9, vitamin b6, lipoic acid and plant extracts for treating circulatory disorders
10/02/2003WO2003080061A1 Inhibition of cell death responses induced by oxidative stress
10/02/2003WO2003080059A1 Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment
10/02/2003WO2003080058A1 Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
10/02/2003WO2003080057A1 Downsized core tablet containing nifedipine
10/02/2003WO2003080056A2 Fine particle size pioglitazone
10/02/2003WO2003080055A1 Pharmaceutical compositions comprising a benzofuran derivative and their use for the treatment of attention deficit/hyperactivity disorder
10/02/2003WO2003080054A1 Use of pyridyl amides as inhibitors of angiogenesis
10/02/2003WO2003080053A1 Combination treatments for chemokine-mediated diseases
10/02/2003WO2003080052A1 A use of treatment for fungal infections with a synergistic formulation of antifungal agents
10/02/2003WO2003080051A1 Method of treating onychomycosis
10/02/2003WO2003080050A1 The use of 3-[1-[2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl]-3,6-dihydro-2h-pyridin-4-yl]-6-chloro-1h-indole or its enantiomers for the treatment of diseases and disorders responsive to 5-ht (serotonin) re-uptake inhibition
10/02/2003WO2003080049A1 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
10/02/2003WO2003080048A1 (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
10/02/2003WO2003080047A1 Phosphate prodrugs of fluorooxindoles
10/02/2003WO2003080046A1 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagoni sts
10/02/2003WO2003080045A1 A process for isolating artemisinin from artemisia annua
10/02/2003WO2003080044A1 Anti-cancer combinations of dmxaa and a nsaid
10/02/2003WO2003080043A1 Topical formulations of resorcinols and cannibinoids and methods of use
10/02/2003WO2003080040A1 Diclofenac sodium oral pharmaceutical
10/02/2003WO2003080039A1 In vivo use of glutathionone s-transferase activated nitric oxide donors
10/02/2003WO2003080038A1 Preventive or therapeutic agent for kidney disease
10/02/2003WO2003080037A2 Use of ltb4 antagonists in veterinary medicine
10/02/2003WO2003080036A2 Use of a vanilloid as an anti-snoring element
10/02/2003WO2003080032A2 Pharmaceutical formulation for the active ingredient budesonide
10/02/2003WO2003080031A1 Sustained release formulation of tramadol
10/02/2003WO2003080029A1 No-donating nsaids adsorbed into carrier particles
10/02/2003WO2003080027A1 Nanoparticulate compositions of angiogenesis inhibitors
10/02/2003WO2003080026A1 Controlled release drug delivery system of pravastatin
10/02/2003WO2003080025A1 Topical composition based on ion-exchange resins, in particular for treating erythemas
10/02/2003WO2003080024A2 Nanoparticulate compositions of map kinase inhibitors
10/02/2003WO2003080022A2 Analgesics for nasal administration
10/02/2003WO2003080021A2 Formulation comprising buprenorphine
10/02/2003WO2003080020A1 Heat-reversible composition treating hyposalia and asialia
10/02/2003WO2003079998A2 Treatment of diseases involving defective gap junctional communication
10/02/2003WO2003079997A2 Prostaglandin f2 alpha analogs in combinaiotn with antimicrobials for treating glaucoma
10/02/2003WO2003079992A2 Pulmonary delivery for levodopa
10/02/2003WO2003079988A2 Use of tagatose in laxatives
10/02/2003WO2003079987A2 A non-selective cation channel in neural cells and methods for treating brain swelling
10/02/2003WO2003079984A2 Substituted tetracycline compounds
10/02/2003WO2003079981A2 Bioadhesive drug delivery system
10/02/2003WO2003079978A2 Protease activity of thrombin inhibits angiogenesis
10/02/2003WO2003079977A2 Novel compositions and methods in cancer associated with altered expression of mcm3ap
10/02/2003WO2003079976A2 A substance with sedative effect
10/02/2003WO2003079974A2 Integrin ligand
10/02/2003WO2003079973A2 Mitotic kinesin inhibitors
10/02/2003WO2003079972A2 Active agent delivery systems and methods for protecting and administering active agents
10/02/2003WO2003079970A2 4-(diarylmethyl)-1-piperazinyl derivatives
10/02/2003WO2003079969A2 Compositions and methods for treating and preventing necrosis
10/02/2003WO2003079965A2 Derivatives of isoflavones
10/02/2003WO2003079945A1 Method of administering buprenorphine to treat depression
10/02/2003WO2003079936A1 Medical devices for delivering anti-proliferative compositions to anatomical sites at risk for restenosis
10/02/2003WO2003079923A1 Method of administering an injectable antibiotic to the ear of an animal
10/02/2003WO2003079886A2 Serotonin and catecholamine system segment optimization techonology
10/02/2003WO2003079885A2 Inhalable sustained therapeutic formulations
10/02/2003WO2003079883A2 Controlled laser treatment for non-invasive tissue alteration, treatment and diagnostics with minimal collateral damage
10/02/2003WO2003079818A1 Alertness bar
10/02/2003WO2003079757A2 Hiv therapeutic
10/02/2003WO2003070177A3 Use of melatonin analogues for induction of general anesthesia
10/02/2003WO2003070168A3 Method of treating inflammation and inflammation-related pain
10/02/2003WO2003064441A3 Oligonucleotides comprising alternating segments and uses thereof
10/02/2003WO2003062414A3 Methods of obtaining isoform specific expression in mammalian cells
10/02/2003WO2003062394A9 Methods and compositions for rna interference
10/02/2003WO2003061638A3 Use of phosphodiesterase antagonists to treat insulin resistance
10/02/2003WO2003061629A3 Dna dosage forms
10/02/2003WO2003061577A3 Polyalkylene glycol with moiety for conjugating biologically active compound
10/02/2003WO2003053358A3 Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
10/02/2003WO2003051370A8 Selective dopamine d3 receptor agonists for the treatment of sexual dysfunction
10/02/2003WO2003050257A3 Targeting leukemia cells
10/02/2003WO2003049747A8 Pharmaceutical composition for use in ophthalmology and rhinology
10/02/2003WO2003049725A3 Compositions for the treatment of lupus, other rheumatic diseases and joint diseases
10/02/2003WO2003047571A3 Use of a kmo inhibitor for producing a pharmaceutical composition
10/02/2003WO2003046180A3 Human cdnas and proteins and uses thereof
10/02/2003WO2003045912A8 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
10/02/2003WO2003044015A3 Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
10/02/2003WO2003042173A8 Nk1 antagonists
10/02/2003WO2003039529A8 Selective antibacterial agents
10/02/2003WO2003039457A3 Anti-mycobacterial compounds
10/02/2003WO2003035694A3 Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
10/02/2003WO2003030811A3 Use of ganoderic acids as cosmetic agents
10/02/2003WO2003028692A3 Acne treatment using oleanolic acid
10/02/2003WO2003020206A3 Use of atazanavir in hiv therapy
10/02/2003WO2003018031A3 Single dose azithromycin for treating respiratory infections
10/02/2003WO2003018022A8 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
10/02/2003WO2003016316A8 Diazacycloalkanes as oxytocin agonists
10/02/2003WO2003009779A3 Delivery of therapeutic capable agents
10/02/2003WO2003002107A3 Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
10/02/2003WO2002099056A3 C22c7orfs as modifiers of the p53 pathway and methods of use
10/02/2003WO2002087552A3 Androgen-mediated neuroprotection and uses thereof
1 ... 5321 5322 5323 5324 5325 5326 5327 5328 5329 5330 5331 5332 5333 5334 5335 5336 5337 5338 5339 5340 5341 ... 7860